Navigation Links
Venaxis to Present at Piper Jaffray 25th Annual Healthcare Conference
Date:11/21/2013

CASTLE ROCK, Colo., Nov. 21, 2013 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will present at the Piper Jaffray 25th Annual Healthcare Conference, to be held December 3-4, 2013, at The New York Palace Hotel in New York, NY. 

Steve Lundy, President and CEO of Venaxis™, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.  Event:Piper Jaffray 25th Annual Healthcare ConferenceDate:Tuesday, December 3, 2013 Time:9:30 am (Eastern Time) Location: 

The New York Palace Hotel, New York, NY The presentation will be webcast live.  To access the webcast, please visit the investor relations section of the Venaxis website at http://ir.venaxis.com. The webcast will be archived and available for 90 days.

Separately, Venaxis is scheduled to ring The NASDAQ Stock Market Closing Bell on December 6, 2013 in a ceremony to celebrate the company's recent achievements as it advances the APPY1 Test toward potential FDA clearance and expands its commercial footprint in the EU.  Venaxis remains on track to complete patient enrollment for its pivotal clinical study of the APPY1 Test in the United States at or around the end of 2013.

About Venaxis, Inc.
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid, protein biomarker-based assay for appendicit
'/>"/>

SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Venaxis APPY1 Test Passes Futility Analysis in Pivotal Clinical Study
2. Venaxis Announces Pricing of Offering of Common Stock and Warrants
3. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
4. Dyadic International To Present At Two Major Conferences In December 2013
5. Sangamo BioSciences Announces Seven Data Presentations At The 2013 American Society of Hematology Annual Meeting
6. Aratana Therapeutics to Present at Two Upcoming Investor Conferences
7. Celladon Corporation Announces Oral Presentation at American Heart Association of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
8. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
9. Accuray to Present at Piper Jaffray 25th Annual Healthcare Conference
10. Cartes 2013: DERMALOG Presents World Firsts in Biometrics
11. Proove Biosciences to Present Research on the Genetics of Pain Medicine and Exhibit at ASRA’s 12th Annual Pain Medicine Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 17, 2014 Athena Signature Series: Turning Cancer ... Beverly Emerson, a professor in the Regulatory Biology Laboratory at ... recent discovery points to an “off switch” for drug resistance ... how her local research is making a global impact in ... and then join host Cheryl K. Goodman, CEO of Social ...
(Date:11/18/2014)... Array Architects is proud of a ... the nation's hospitals and health systems. It is a ... their careers to the advancement of both the healthcare ... respective field, Laura Silvoy has been chosen to share ... Simulation Conference. , Laura will present her Process ...
(Date:11/17/2014)... November 17, 2014 The new ... Weights " describes the challenges of becoming the ... accredited status for calibration weights in the microgram ... weight manufacturers and any scientists involved in nanotechnology ... design, handling, manufacturing and calibration of weights in ...
(Date:11/15/2014)... New York, NY (PRWEB) November 14, 2014 ... expansion plan, QuickSTAT is making significant investments in ... evolving world of modern cold chain and the ... will support QuickSTAT’s ongoing focus on customized logistics ... Towers and enhancement of existing facilities. There will ...
Breaking Biology Technology:Array Healthcare Simulation Expert Slated to Speak at Winter Simulation Conference 2New White Paper on Microgram Weights Describes How to Achieve Traceable Measurement Down to 0.05 Milligrams 2QuickSTAT Announces Global Expansion Plan to Enhance Its Global Network and Cold Chain Logistics Capabilities for Life Sciences 2
... The Foundation for,Biomedical Research (FBR) congratulates Congress for ... highest civilian honor it can bestow, the,Congressional Gold ... medicine,have improved the health of millions of American ... as a surgeon, inventor, educator and,medical statesman make ...
... Third Genmab Antibody,Summary: Genmab,s Partner Roche has Filed a CTA With ... ... Antibody, COPENHAGEN, October 2 Genmab A/S (OMX: GEN),announced today ... the British Medicines and Healthcare products,Regulatory Agency (MHRA) for a Genmab ...
... Presentation To Be Webcast -, MONTVALE, N.J., Oct. ... today that Noah Berkowitz, M.D., Ph.D.,President and Chief Executive ... October 11, 2007 at 11:00 a.m. PT. BIO InvestorForum ... the Palace Hotel in San Francisco, CA. Dr. ...
Cached Biology Technology:Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal 2Genmab A/S - Company Announcement 2Synvista Therapeutics to Present at the BIO InvestorForum 2007 2Synvista Therapeutics to Present at the BIO InvestorForum 2007 3
(Date:11/18/2014)... Nov. 17, 2014   News ... collaborate to develop The Partners Data Lake, an ... Partners Data Lake will allow researcher and clinicians ... treatment and the lives of patients , ... clinical activities across the Partners system, breaking down ...
(Date:11/18/2014)... NEW YORK , Nov. 18, 2014 /PRNewswire/ ... iris-based identity authentication solutions, and MorphoTrust USA ... solutions and services, today announced a strategic partnership ... across enterprise, motor vehicle administration (MVA), airport screening ... leader in identity-related solutions, MorphoTrust serves consumers through ...
(Date:11/12/2014)... 2014 Crossmatch™, a leading provider of biometric ... fingerprint readers have been deployed throughout Montparnasse Pasteleria, ... Mexico . The bakery chain implemented the Crossmatch ... caused by employees clocking in for each other. ... Montparnasse relied on paper timecards and a mechanical time ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... the waters off the North Carolina coast, historically-significant World ... a testament to a relatively unknown chapter in U.S. ... are not only important for their cultural value, but ... invertebrates and algal species. Additionally, due to their unique ...
... 24, 2011 A team of scientists from The ... to kill the deadliest antibiotic-resistant bacteria. The compound could ... life-threatening and highly resistant bacterial infections. The results ... Journal of the American Chemical Society . ...
... AURORA, Colo. (Aug. 24, 2011) A scientist investigating ... motor coordination has found that key eye reflexes are substantially ... Medicine researcher Alberto Costa, MD, Ph.D., could lead to new ... aimed at improving quality of life for those with this ...
Cached Biology News:Scientists reengineer antibiotic to overcome dangerous antibiotic-resistant bacteria 2Scientists reengineer antibiotic to overcome dangerous antibiotic-resistant bacteria 3Scientists reengineer antibiotic to overcome dangerous antibiotic-resistant bacteria 4Researcher finds altered cerebella in those with Down syndrome 2
Request Info...
...
...
... agent. Inhibits several important steps of angiogenesis including ... cells. Also reduces intracellular reactive oxygen species (ROS) ... endothelial cells. Formula: ... MolWeight: 360.31484 ...
Biology Products: